UK telehealth marketing under MHRA and ASA in 2026: what's allowed and what isn't

Marketing a UK telehealth service in 2026 is more constrained than founders coming from consumer ecommerce often realise. Prescription-only medicines cannot be advertised to the public. Brand-name comparisons of POMs are prohibited. Testimonials for prescription products attract ASA and MHRA enforcement. This piece is the operator's brief on what UK telehealth marketing can and cannot say — useful before signing off a campaign, not after the regulator engages.

The rulebook — three sources operators need to know

Three documents govern UK telehealth marketing. The Human Medicines Regulations 2012 (HMR) — the statutory framework that prohibits public advertising of prescription-only medicines. The CAP Code enforced by ASA — the advertising self-regulation framework with specific medicines, health, and beauty sections. MHRA's Blue Guide — practical guidance on advertising and promotion of medicines.

Operators don't need to memorise the documents but they need to know they exist and where the lines sit. Marketing legal review should reference all three. Brands that operate on consumer-ecommerce instincts without this grounding consistently cross the line, often without realising it.

What you can market — the clinical service and the operator

Permitted: the clinical service (consultation, ongoing care, follow-up), the operator (clinical credentials, GPhC registration, CQC where applicable), the patient experience (convenience, discretion, response times), and category-level information (what conditions you treat, how you assess, what monitoring looks like).

Patient testimonials about the service experience (without naming medicines or claiming specific outcomes) are permitted. Branded clinical service identity is permitted. Marketing the operator's reputation, infrastructure, and substance is broadly permitted. What you cannot do is shift from marketing the service to marketing the medicine.

What you cannot market — POMs by name, brand comparisons, efficacy claims

Prohibited: naming a POM in patient-facing marketing (Ozempic, Wegovy, Mounjaro, sildenafil, finasteride, methylphenidate, SSRIs by brand, etc.). Comparing one branded POM to another. Making efficacy claims tied to a specific medicine. Using testimonials that name medicines or claim specific medical outcomes. Implying medicine specificity ('we prescribe [Brand X]' or 'our patients use [Brand X]').

The line between marketing the service and marketing the medicine is the central regulatory boundary. ASA and MHRA enforcement across 2024-2026 has consistently been on operators that cross this line — usually because of testimonial creep, comparative claims, or branded-medicine naming in social ads.

Common patterns that catch operators out

Five patterns to watch. 1) Influencer or testimonial videos that name the medicine the patient is on. 2) Comparison tables that list branded GLP-1s side by side. 3) Landing pages with 'Get [BrandX] from £X/month' headlines. 4) Social ad copy that says 'we prescribe Wegovy' or similar. 5) Email subject lines or push notifications that name medicines.

All five are common, all five are non-compliant. The marketing team that learned the rules from consumer ecommerce will instinctively reach for these patterns. The compliance team needs to set the boundary at design time, not catch it in QA.

How to design compliant marketing that still converts

Three practical approaches. First, anchor the messaging on the patient need and the clinical service, not the medicine — 'medical weight management with ongoing clinical support' instead of 'get Wegovy here'. Second, use category-level efficacy framing rather than branded — 'GLP-1 medications have been shown to support meaningful weight loss in clinical trials' is permitted; '[Brand X] achieves Y% weight loss' is not. Third, lead testimonials with patient experience of the service, not the medicine.

Compliant marketing converts when it competes on substance — clinical depth, ongoing care, operator reputation, patient experience. The brands that compete on the medicine are increasingly losing to brands that compete on the service. Compliance becomes a positioning advantage, not just a constraint.

How PExpo supports compliant marketing for brand customers

PExpo's brand model includes marketing review as part of the operational support — particularly important for category launches in weight management, ED, hair loss, and mental health where MHRA enforcement has been most active. The clinical workflow documentation provides the substance brands can market on; the regulatory awareness is built into the model.

For brands launching with PExpo, marketing compliance is a foundational design conversation, not a launch-blocker. See our brand model page for the operational scope or our [MHRA enforcement trends piece](mhra-enforcement-trends-uk-telehealth.html) for the broader regulatory context.

Compliant marketing converts when it competes on substance. The brands that compete on the medicine are increasingly losing to brands that compete on the service. Compliance becomes a positioning advantage, not just a constraint.

UK telehealth marketing is more constrained than consumer ecommerce instincts suggest — but the constraints are clear once known, and compliant marketing increasingly outperforms boundary-pushing marketing as the category matures. See our brand model page for PExpo's brand operations including marketing review, our MHRA enforcement trends piece, or our ASA/CAP rules guide.

Frequently asked questions